The EluNIR-PERL drug-eluting stent is used for the treatment of coronary artery disease.
Medinol announced that its EluNIR-PERL drug-eluting stent (DES) received approval from FDA. The device is used in the treatment of coronary heart disease.
The design of the stent allows for more precise navigation and placement in complex anatomies.
In a press release, Medinol CEO Yoram Richter said, “We are pleased to bring technologies to the U.S. that focus both on benefit to patients as well as unique and meaningful advantages to surgeons, allowing for precise stent placement, shorter procedure times and reduced radiation exposure.”
In the same press release, CoSo Health CEO Jae Lee stated that CoSo would distribute the device.
"We are proud to distribute one of the world's best drug-eluting stents via our intuitive and easy-to-use SaaS+ platform, which reduces layers in the supply chain," Lee said.
(Oct 24 2023); CoSo Health; Medinol Receives FDA Approval for Next Generation EluNIR-PERL Drug-Eluting Coronary Stent System; https://www.prnewswire.com/news-releases/medinol-receives-fda-approval-for-next-generation-elunir-perl-drug-eluting-coronary-stent-system-301965041.html
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.